EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Hyperactivated Macrophage‐Based Biohybrid Platform for Spatiotemporally Controlled Immunoregulatory and Sonodynamic Therapy of Cancer

Mengchun Chen, Yingnan Xiao, Huizhe Chen, Weian Mao iD, Jiale Quan iD, Yunxuan Huang, Jing Wu, Wenzhen Gao, Ziyi Wang, Keyu Long, Dedong Yu, Xinji Wang and 8 more

Advanced Science · 2026-11-15

DOI: 10.1002/advs.78777 ↗

At a glance

Journal article in Advanced Science, published online on 2026-11-15. Written by Mengchun Chen and 19 co-authors. Institution: Department of Pharmacy, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China. 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Outstanding Youth Fund Project of Zhejiang Natural Science Foundation, Key Project of Zhejiang Natural Science Foundation.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Reprogramming the immunosuppressive tumor microenvironment (TME) is pivotal for enhancing cancer immunotherapy. This study introduces a biohybrid platform, HM‐LCPs, which combines hyperactivated macrophages (HMs) with ultrasound (US)‐responsive liposomal nanobubbles (LCPs) to sequentially remodel the immunosuppressive TME via spatiotemporally controlled immunomodulation and sonodynamic therapy (SDT). HMs consistently release IL‐1β, independent of the immunosuppressive TME. Coupling oxygen‐loaded, Ce6‐containing LCPs with HMs yields stable HM‐LCPs that preserve macrophage function and enable ROS generation upon US activation. Through immunoregulatory effects, HM‐LCPs directly induce immunogenic cell death (ICD) in tumor cells, enhance dendritic cell maturation, and inhibit fibronectin production in fibroblasts. Subsequent US irradiation further amplifies these effects, leading to significant tumor growth inhibition, enhanced ICD, extracellular matrix remodeling, and increased CD8 + T cell infiltration, thereby converting the TME from immunosuppressive to immunoactive. Additionally, treatment of the primary tumor with HM‐LCPs and US induces a robust abscopal effect, effectively halting distant tumor progression. Collectively, HM‐LCPs function as an intelligent platform that integrates immune activation and SDT to sequentially reprogram the TME and enhance antitumor immunity.

Subjects

Author keywords

immunogenic cell deathimmunotherapymacrophagesnanobubblesonodynamic therapy

Authors and institutions

  • Department of Pharmacy, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
  • Department of Pharmaceutics, Zhejiang Provincial Key Laboratory of Drug Discovery and Development for Metabolic Diseases, School of Pharmaceutical Sciences of Wenzhou Medical University, Wenzhou, People's Republic of Ch…
  • Yongzhou Vocational Technical College, Yongzhou, People's Republic of China.
  • Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
  • Wenzhou Medical University, Wenzhou, People's Republic of China.
  • Zhejiang Engineering Research Center for Innovation and Application of Intelligent Radiotherapy Technology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.

ORCID profiles: Weian Mao, Jiale Quan, Yijie Chen

Funding

  • National Natural Science Foundation of China
  • Outstanding Youth Fund Project of Zhejiang Natural Science Foundation
  • Key Project of Zhejiang Natural Science Foundation
  • Key Project of Ningbo Science and Technology Bureau
  • Exploratory Project of Zhejiang Natural Science Foundation
  • Youth Fund Project of Zhejiang Natural Science Foundation
  • Basic Scientific Research Project of Wenzhou Science and Technology Bureau
  • Oncology Discipline Group, the Second Affiliated Hospital of Wenzhou Medical University, China

Cite

APA

Chen, M., Xiao, Y., Chen, H., Mao, W., Quan, J., Huang, Y., Wu, J., Gao, W., Wang, Z., Long, K., Yu, D., Wang, X., Pan, X., Wang, W., Zhang, X., Sun, W., Lin, X., Zhao, Y., Zhuge, D., & Chen, Y. (2026). Hyperactivated Macrophage‐Based Biohybrid Platform for Spatiotemporally Controlled Immunoregulatory and Sonodynamic Therapy of Cancer. Advanced Science. https://doi.org/10.1002/advs.78777

Vancouver

Chen M, Xiao Y, Chen H, Mao W, Quan J, Huang Y, et al. Hyperactivated Macrophage‐Based Biohybrid Platform for Spatiotemporally Controlled Immunoregulatory and Sonodynamic Therapy of Cancer. Advanced Science. 2026. doi:10.1002/advs.78777

BibTeX
@article{Chen2026,
  author = {Chen, Mengchun and Xiao, Yingnan and Chen, Huizhe and Mao, Weian and Quan, Jiale and Huang, Yunxuan and Wu, Jing and Gao, Wenzhen and Wang, Ziyi and Long, Keyu and Yu, Dedong and Wang, Xinji and Pan, Xiehua and Wang, Wenqian and Zhang, Xufei and Sun, Wei and Lin, Xiaoji and Zhao, Yingzheng and Zhuge, Deli and Chen, Yijie},
  title = {Hyperactivated Macrophage‐Based Biohybrid Platform for Spatiotemporally Controlled Immunoregulatory and Sonodynamic Therapy of Cancer},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.78777}
}
Start for free →